FDA orders GLP-1 eye-risk warnings: what patients should know

The Food and Drug Administration is requiring new safety information on GLP-1 medicines after finding a potential increased risk of a rare eye condition that can cause permanent vision loss. The November 9 announcement covers the drug class, rather than only one brand used for weight loss or diabetes.

For patients, the immediate message is to take sudden changes in eyesight seriously and contact a health professional right away. The announcement is a labeling action, not a recall or a direction for every person taking one of these medicines to stop. Decisions about continuing treatment belong in an individualized discussion with the prescriber.

Which medicines are affected?

The FDA’s safety communication lists medicines used for type 2 diabetes, weight management and other approved indications. Among the familiar names are Ozempic, Wegovy, Rybelsus, Mounjaro and Zepbound. The list also includes older members of the class and combination products. This is not a warning limited to an injectable formulation or to people taking a medicine solely to lose weight.

Reuters reported the action on November 9, identifying Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound among the affected products. The Associated Press also reported the class-wide change. Those news reports corroborate the announcement; the FDA’s own communication provides the detailed patient advice and evidence.

Different products have different active ingredients and approved uses. Semaglutide is the ingredient in Ozempic, Wegovy and Rybelsus. Tirzepatide, used in Mounjaro and Zepbound, acts on both GIP and GLP-1 receptors. A shared warning does not mean that every product has been studied in exactly the same population or that a precise, identical risk has been established for each brand.

What is NAION?

NAION involves reduced blood flow to the front of the optic nerve, the structure that carries visual information from the eye to the brain. The FDA says the underlying cause is not completely understood. Vision may decline suddenly without pain, often in one eye, and the damage can be permanent.

Symptoms can include blurred or missing areas of vision, blind spots, tunnel vision, distorted colors or reduced sharpness in the center of what a person sees. Some patients notice the change when they wake up. The absence of pain should not be interpreted as reassurance that a new visual problem can wait.

A news report cannot diagnose NAION. Other conditions can also change vision, and determining the cause requires clinical evaluation. The FDA advises clinicians to arrange prompt assessment by an ophthalmologist when NAION is suspected. Patients should describe what changed, when it began and which eye appears affected, rather than assuming that a particular medication must be the explanation.

How large was the risk in the FDA’s analysis?

The FDA pooled 126 randomized controlled trials involving 134,253 patients. It identified 15 probable NAION events: 10 among people receiving GLP-1 medicines and five among people receiving placebo. None were identified in the group receiving other glucose-lowering medicines included in that analysis.

Because participants were followed for different amounts of time, the agency reported rates in person-years. One person followed for one year contributes one person-year; the measure combines the number of people observed with their follow-up time. It is not the same as counting a fixed percentage of all prescriptions or all injections.

The resulting rates were 6.4 events per 100,000 person-years in the GLP-1 group and 3.8 in the combined comparison group. Subtracting those rates gives an observed difference of 2.6 events per 100,000 person-years. That calculation helps show the scale of the difference, but it is not a personalized forecast or proof that every extra event was caused by the medicine.

The small event count is important context. A potentially serious outcome can justify a warning even when it is uncommon, while a warning should not be rewritten as a claim that vision loss is frequent. Both parts of the finding matter: the possible increase and the rarity of the condition.

Why is the evidence not a simple yes-or-no answer?

The FDA reviewed more than the clinical trials. Its assessment also considered animal findings, reports submitted after medicines reached the market and observational research. Reports of events after treatment can raise a signal, but they do not by themselves show what caused the event.

One difficulty is that NAION risk factors overlap with health problems common among people prescribed these medicines. The FDA lists diabetes, high blood pressure, sleep apnea, smoking, anemia and kidney disease among possible risk factors. A person may therefore have more than one reason for being at risk, regardless of treatment.

The agency’s separate study of adults with type 2 diabetes illustrates why the comparison matters. It found no statistically significant increase when GLP-1 users were compared with people starting SGLT-2 inhibitors. It did find an increased risk compared with people starting DPP-4 inhibitors. These are different comparison treatments, not interchangeable control groups.

Those results do not cancel the labeling decision, nor do they establish that the same risk estimate applies to everyone. The FDA concluded that the total evidence supported a potential increased risk and required the warning. It also reported that its animal-data review did not identify a mechanism explaining how GLP-1 use might increase NAION risk.

Is this the first regulatory warning?

No. European regulators reached an earlier decision focused on semaglutide. In June 2025, the European Medicines Agency’s safety committee concluded that NAION was a very rare side effect of semaglutide medicines, including Ozempic, Rybelsus and Wegovy, and recommended updated product information.

The European assessment described “very rare” as potentially affecting up to one in 10,000 people taking semaglutide. It also discussed epidemiological findings corresponding to approximately one additional case per 10,000 person-years of treatment. Those figures come from a different assessment and should not be substituted for the FDA’s pooled trial rates.

The distinction is also about scope. Europe’s announcement concerned semaglutide; the November 9 U.S. communication requires information across the GLP-1 class. Treating the two announcements as identical would obscure what is new in the American action.

What should patients discuss with their clinician?

The FDA tells patients with symptoms to contact a health professional immediately. Someone who has already experienced NAION should discuss whether to continue or stop a GLP-1 medicine. For clinicians, the agency says discontinuation should be considered in patients who develop NAION unless treatment benefits clearly outweigh the risk.

That is different from a blanket recommendation that all users stop. The reason for treatment, previous eye problems, other medical conditions and the benefits being achieved can affect the decision. Some medicines in this group have additional approved cardiovascular, kidney or other indications, so a conversation should consider the whole treatment plan.

A practical appointment discussion can cover the exact medicine being taken, any history of NAION, new visual symptoms and how to obtain urgent eye care if a change occurs. Patients should not wait for a routine appointment to report sudden vision loss. This article provides general information, not a diagnosis or an individual medication recommendation.

What happens next?

The FDA is requiring manufacturers to add NAION information to the warnings and precautions section of their labels. The agency’s communication does not establish that every package or online label has already been updated. Patients and prescribers should use the latest product information and discuss the new warning in the context of individual care.

For now, the useful takeaway is specific: know the symptoms, seek prompt assessment for sudden visual changes and make treatment decisions with a clinician. A headline about possible harm should neither dismiss a serious symptom nor replace a patient’s medical care.

More NewsCubby health reporting

Our explanation of the CDC’s early flu-season report separates warning signals from predictions about individual risk. Our guide to hospital facility fees explains another practical part of navigating medical care: understanding how an appointment may be billed.

Want more? Explore today’s headlines on NewsCubby and join My Day free to make NewsCubby part of your day.

NewsCubby articles are produced with AI assistance.

Factual sources

FDA: November 9, 2026 drug safety communication

https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential

Reuters: U.S. FDA orders new eye risk warnings for Ozempic, Zepbound (via Investing.com)

https://www.investing.com/news/stock-market-news/us-fda-orders-new-eye-risk-warnings-for-ozempic-zepbound-5012770

Associated Press / Matthew Perrone: FDA adds rare vision-loss warning (via ABC News)

https://abcnews.com/amp/Health/wireStory/fda-adds-rare-vision-loss-warning-popular-glp-137987540

European Medicines Agency: June 2025 semaglutide NAION review

https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy